Over 1,200 adverse events in US after receiving Moderna Covid-19 vaccine

The US Food and Drug Administration issued an Emergency Use Authorization for Moderna Covid-19 vaccine on December 18, 2020, administered as 2 doses, 1 month apart to prevent Covid-19

Vaccine, Moderna
108 case reports were identified for further review as possible cases of a severe allergic reaction, including anaphylaxis.
IANS Washington
2 min read Last Updated : Jan 23 2021 | 8:53 AM IST

Over 1,200 adverse events were reported after receipt of Moderna Covid-19 vaccine as of January 10, with 10 cases determined to be anaphylaxis, according to a report released by the US Centers for Disease Control and Prevention (CDC) on Friday.

The US Food and Drug Administration issued an Emergency Use Authorization for Moderna Covid-19 vaccine on December 18, 2020, administered as 2 doses, 1 month apart to prevent Covid-19, the Xinhua news agency reported.

As of January 10, a reported 40,41,396 first doses of Moderna Covid-19 vaccine had been administered in the US, and reports of 1,266 adverse events after receipt of Moderna Covid-19 vaccine were submitted to the Vaccine Adverse Event Reporting System, according to the CDC.

Among these, 108 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis.

Anaphylaxis is a life-threatening allergic reaction that occurs rarely after vaccination, with onset typically within minutes to hours.

Among these case reports, 10 cases were determined to be anaphylaxis, a rate of 2.5 anaphylaxis cases per million Moderna Covid-19 vaccine doses administered, said the CDC.

The median interval from vaccine receipt to symptom onset was 7.5 minutes.

The CDC urged locations administering Covid-19 vaccines to adhere to CDC guidance, including screening recipients for contraindications and precautions, having necessary supplies and staff members available to manage anaphylaxis, implementing recommended post-vaccination observation periods, and immediately treating suspected anaphylaxis with intramuscular epinephrine injection.

--IANS

int/rs/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Jan 23 2021 | 8:51 AM IST

Next Story